Loxicom 5mg/ml Solution for Injection For Dogs and Cats

Loxicom 5mg/ml Solution for Injection For Dogs and Cats.

Presentation

Each ml contains:

Meloxicam 5 mg/ml
Sodium Benzoate 150 mg/ml

Uses

Dogs: Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.
Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Dosage & Administration

Dosage and Administration for Dogs:

Musculo-skeletal disorders: Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg bodyweight). Loxicom 1.5 mg/ml oral suspension and Loxicom 0.5 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours): Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg bodyweight) before surgery, for example at the time of induction of anaesthesia.

Particular care should be taken with regard to the accuracy of dosing. Avoid the introduction of contamination during use.

Dosage and Administration for Cats:

Reduction of post-operative pain: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e. 0.06 ml/kg bodyweight) before surgery, for example at the time of induction of anaesthesia.

Particular care should be taken with regard to the accuracy of dosing. Avoid the introduction of contamination during use.

Contraindictions, Warnings etc

Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

Typical adverse reactions of non-steroidal anti-inflammatory drugs NSAIDs such as loss of
appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally
been reported. In dogs, these adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

In the case of overdose symptomatic treatment should be initiated
Pharmaceutical Precautions

This veterinary medicinal product does not require any special storage conditions.
Shelf-life after first opening the container: 28 days.
Do not use after the expiry date stated on the carton and the bottle.
Further Information

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, antiexudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase 2 (COX 2) to a greater extent than cyclooxygenase 1 (COX 1).

Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73?g/ml in dogs and 1.1 ?g/ml in cats were reached approximately 2.5 hours and 1.5 hours postadministration, respectively.

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs. More than 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats. In dogs, meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative
and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. Meloxicam is eliminated with a half-life of 24 hours in dogs and 15 hours in cats. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.